Snowball logo
logo
IMVI

IMVIF

IMVIF • PINK
$0.002$0.00  (0%)
Estimate
EPS
-45.5
Beta
4,085.991
About the company
Ticker
IMVIF
ISIN
Country
Canada
Sector (GICS)
Other
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX, an immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.

Frequently asked questions

What sector does IMVIF (IMVIF) operate in?

IMVIF belongs to the Other sector and operates in the Biotechnology industry.

What is IMVIF (IMVIF) current stock price?

As of the latest data, IMVIF stock price is $0.00, with a previous close of $0.00.

What is IMVIF (IMVIF) current market capitalization?

IMVIF market cap is approximately 23.42 thousand.

What is IMVIF (IMVIF) Earnings Per Share (EPS)?

The trailing EPS is -$45.50.

Does IMVIF (IMVIF) pay dividends?

No. IMVIF does not pay a dividend.

What is IMVIF (IMVIF) beta (volatility) score?

IMVIF has a beta of 4085.991, indicating very high volatility compared to the market.